SequelSEC

NeuroPace Inc NPCE

Surgical & Medical Instruments & Apparatus · CIK 0001528287 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$98.84M
Fiscal year ended 2026-06-30
Operating income
-$15.08M
Fiscal year ended 2026-06-30
Free cash flow
-$11.61M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$306.20MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$9.09Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity16.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.3%5th
Long-term debt / equity3.09x94th
Gross margin77.2%85th
Current ratio5.28x77th
Revenue YoY growth25.1%71th
R&D / revenue27.9%63th
SBC / revenue11.1%61th
Operating margin-16.3%53th
FCF margin-11.3%51th
Net margin-21.5%51th

NeuroPace Inc (NPCE) reported revenue of $98.84M and net income of -$19.11M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from NeuroPace Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NeuroPace Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$98.84M
Cost of revenue$20.14M
Gross profit$78.70M
Operating income-$15.08M
Net income-$19.11M
Research & development$27.69M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$66.09M
General & administrative$18.85M
Selling & marketing$47.24M

Balance

NeuroPace Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$12.54M
Total assets$96.99M
Current assets$86.19M
Total liabilities$85.11M
Current liabilities$17.43M
Total equity incl. NCI$11.88M
Temporary (mezzanine) equityUnavailable
Inventory$18.11M
Accounts receivable$14.93M
GoodwillUnavailable
Long-term debt$59.01M
Accounts payable$4.20M

Cash flow

NeuroPace Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$11.24M
Capital expenditures$369.00K
Investing cash flow-$369.00K
Financing cash flow$1.41M
Net change in cash-$10.20M
Stock-based compensation$9.82M
Common dividends paidUnavailable
Common share repurchases$0
Depreciation & amortizationUnavailable

Derived

NeuroPace Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$11.61M
Gross margin79.6%
Operating margin-15.3%
FCF margin-11.7%
SBC / revenue9.9%
Current ratio4.94x
Revenue YoY growth16.9%
Net margin-19.3%
R&D / revenue28.0%
CapEx / revenue0.4%
Long-term debt / equity4.97x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NPCE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.